Document 2385
 DOCN  M94A2385
 TI    Seroconversion to dual reactivity among HIV-1 and HIV-2 seropositive
       women in Abidjan, Cote d'Ivoire.
 DT    9412
 AU    Wiktor SZ; Ekpini E; Sibailly T; Diaby L; Teurquetil MJ; Tossou O;
       DeCock KM; Greenberg AE; Projet RETRO-CI, Abidjan, Cote d'Ivoire.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):316 (abstract no. PC0195). Unique
       Identifier : AIDSLINE ICA10/94370190
 AB    OBJECTIVE: To assess the rate of seroconversion from HIV-negative
       (HIV-N) to HIV-1 or HIV-2 seropositivity and from HIV-1 or HIV-2
       seropositivity to dual reactivity (HIV-D) in a cohort of women enrolled
       in a study of perinatal HIV transmission in Abidjan, Cote d'Ivoire.
       METHODS: From September 1990 to August 1992, HIV-1, HIV-2, and HIV-N
       women were enrolled at delivery and followed until January 1994.
       Six-monthly blood samples were screened for HIV antibodies by EIA and
       confirmed by a synthetic peptide-based test (Peptilav) or Western blot.
       HIV serotype (HIV-1, HIV-2, or HIV-D) was determined by Peptilav, and
       seroconversion (SC) was defined as a change in Peptilav result.
       Lymphocyte subtyping was performed. TABULAR DATA, SEE ABSTRACT VOLUME.
       CONCLUSIONS: SC to dual reactivity occurs at similar rates in HIV-1 and
       HIV-2 women, occurs at higher rates than does SC from HIV-N to HIV-1 or
       HIV-2 seropositivity, and tends to be associated with more advanced
       immunosuppression. These data suggest that immunosuppressed HIV
       seropositive women may be more susceptible to HIV-1 or HIV-2 infection
       than are seronegative women and/or that dual reactivity may be a marker
       for immunosuppression. Virologic testing will help to investigate these
       two possibilities.
 DE    Cohort Studies  Female  Human  HIV Infections/IMMUNOLOGY  *HIV
       Seropositivity  HIV-1/*IMMUNOLOGY  HIV-2/*IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).